Until recently, limited options were available in acute myeloid leukemia (AML). The approval of 8 new agents or formulations in the last 2 years has caused a paradigm shift in AML management, centered on incorporation of targeted agents interrupting key dysregulated enzymes. This interactive infographic focuses on the FLT3 mutation, its clinical implications, testing strategies, and the safety/efficacy of new and emerging FLT3 inhibitors.
Upon completion of this activity, participants should be better able to:
Harvard Medical School
Associate Physician, Medicine
Brigham and Women’s Hospital
Clinical Director, Adult Leukemia Program
Dana-Farber Cancer Institute
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources